enGene Therapeutics (ENGN) Convertible Debt (2022)
enGene Therapeutics (ENGN) posted quarterly Convertible Debt of $17.4 million for Q4 2022.
enGene Therapeutics (ENGN) Convertible Debt (2022) Analysis & Trends
enGene Therapeutics (ENGN) has reported Convertible Debt for 1 consecutive years, with $17.4 million the latest figure, recorded in Q4 2022.
- In Q4 2022, Convertible Debt changed N/A year-over-year to $17.4 million; the TTM figure through Oct 2022 stood at $17.4 million (changed N/A YoY), while the FY2022 annual figure was $17.4 million, changed N/A from the prior year.
- Convertible Debt held at $17.4 million in Q4 2022 per ENGN's latest filing.
- Across five years, Convertible Debt topped out at $17.4 million in Q4 2022 and bottomed at $17.4 million in Q4 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.71 Bn | 131.86 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 86.55 Bn | 78.55 Bn | 3.93 Bn |
| 3 | Argenx Se | 65.26 Bn | 60.07 Bn | 1.37 Bn |
| 4 | Moderna | 59.81 Bn | 54.67 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 42.16 Bn | 37.06 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.87 Bn | 28.56 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.13 Bn | 9.74 Bn | 668.28 Mn |
| 8 | Insmed | 27.53 Bn | 26.37 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.31 Bn | 26.47 Bn | - |
| 10 | enGene Therapeutics | 124.46 Mn | 124.46 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Oct 31, 2022 | 17.41 Mn |